Welcome to our dedicated page for Sight Sciences SEC filings (Ticker: SGHT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sight Sciences SEC filings document the company’s ophthalmic medical device business, segment operating results, governance, capital structure, and material events. Form 8-K filings report quarterly and annual financial results, investor presentation materials, and Regulation FD disclosures tied to the company’s Interventional Glaucoma and Interventional Dry Eye operations.
The filing record also includes definitive proxy materials for annual meeting matters, disclosures on executive officer changes and compensatory arrangements, material agreements such as lease amendments, and legal disclosures involving interventional glaucoma patents. These filings frame SGHT’s public reporting around product commercialization, intellectual property, corporate governance, risk factors, and shareholder voting matters.
Sight Sciences director and 10% owner Staffan Encrantz reported an open-market purchase of 14,100 shares of Common Stock at a weighted average price of $4.879 per share. After this trade, he directly holds 1,434,283 shares, including 28,261 restricted stock units subject to vesting as previously reported.
He also reports indirect interests in 5,086,920 shares held by the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust, where he is a trustee, and 632,456 shares held by Allegro Investment Fund, L.P. He disclaims beneficial ownership of Allegro’s shares and of the trust and fund holdings beyond any pecuniary interest.
Fountain Tamara reported acquisition or exercise transactions in this Form 4 filing.
Sight Sciences director Tamara Fountain received an equity grant in the form of restricted stock units. She was awarded 28,261 RSUs on June 4, 2026 under the company’s Non-Employee Director Compensation Program, representing approximately $130,000 of common stock based on the closing price that day.
The RSUs vest on the earlier of June 4, 2027 and the company’s 2027 annual meeting of stockholders, subject to her continued board service. Following this grant, she holds 109,650 shares and units in total, including 81,389 shares of common stock and 28,261 unvested RSUs.
Encrantz Staffan reported acquisition or exercise transactions in this Form 4 filing.
Sight Sciences director Staffan Encrantz received an equity award in the form of restricted stock units (RSUs). He was granted 28,261 RSUs under the company’s Non-Employee Director Compensation Program, with the number of units based on approximately $130,000 of common stock at the closing price on June 4, 2026.
The RSUs vest on the earlier of June 4, 2027 or the company’s 2027 annual stockholder meeting, contingent on his continued board service. Following this grant, his direct holdings include 1,391,922 shares of common stock plus the 28,261 RSUs, totaling 1,420,183 shares. Additional indirect positions are reported through the 1997 Staffan and Margareta Encrantz Revocable Trust and Allegro Investment Fund, L.P., with beneficial ownership of those shares disclaimed as described in the footnotes.
Burbach Gerhard F reported acquisition or exercise transactions in this Form 4 filing.
Sight Sciences, Inc. reported that director Gerhard F. Burbach received a grant of 28,261 restricted stock units (RSUs) under the company’s Non-Employee Director Compensation Program. The award equals approximately $130,000 of common stock based on the closing price on June 4, 2026.
The RSUs vest on the earlier of June 4, 2027 or the company’s 2027 annual stockholder meeting, if he continues serving as a director through that date. Following this grant, he directly holds a total of 123,207 common shares and RSUs, including 44,922 shares of common stock and RSUs from current and prior awards.
Zurbay Donald reported acquisition or exercise transactions in this Form 4 filing.
Sight Sciences director Donald Zurbay received a grant of 28,261 restricted stock units (RSUs) under the company’s Non-Employee Director Compensation Program. The award value is approximately $130,000, based on the closing price of the common stock on June 4, 2026.
The RSUs vest on the earlier of June 4, 2027 or the company’s 2027 annual stockholder meeting, as long as Zurbay continues serving on the board through that date. After this grant, he has a total reported position of 193,613 shares and rights, including common shares, unvested RSUs, and stock options exercisable within 60 days.
Mazzacco Catherine reported acquisition or exercise transactions in this Form 4 filing.
Sight Sciences director Catherine Mazzacco received an equity grant as board compensation. She was awarded 28,261 restricted stock units (RSUs) of common stock on June 4, 2026 at no cash cost, equal to approximately $130,000 based on the closing price that day.
The RSUs vest on the earlier of June 4, 2027 or the company’s 2027 annual meeting of stockholders, subject to her continued service on the board. After this grant, she holds 69,276 shares and RSUs directly, and 37,492 shares indirectly through an irrevocable trust where she is the beneficiary.
Sight Sciences, Inc. reported the results of its annual stockholder meeting held on June 4, 2026. A total of 41,456,258 shares were present or represented by proxy, which was about 76.2% of the 54,403,542 shares outstanding as of the April 8, 2026 record date.
Stockholders elected Class II directors Gerhard Burbach and Staffan Encrantz to serve until the 2029 annual meeting or until their successors are elected. They also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. No other matters were brought for a vote.
Sight Sciences, Inc. Chief Operating Officer Alison Bauerlein reported a sale of 12,728 shares of Common Stock on May 18, 2026 at a weighted average price of $5.12 per share. According to the disclosure, these shares were sold to cover her tax liability arising from recently vested restricted stock units.
After this tax-related sale, Bauerlein directly holds 688,893 shares, which includes 169,810 shares of Common Stock and 519,083 shares that are scheduled to be issued as her remaining RSUs vest and settle over time.
SGHT filed a Form 144 notice reporting proposed sales of Common Stock by an affiliate under Rule 144. The filing lists 12,728 shares described as vested restricted stock to be sold on 05/15/2026 and discloses prior sales of 25,874 shares on 04/02/2026.
The filing shows dollar amounts tied to transactions ($65,129.18 and $90,007.90) and identifies Fidelity Brokerage Services LLC as the broker. The notice is a regulatory filing of intended and recent sales; cash‑flow recipients and timing beyond the listed dates are not detailed here.
Sight Sciences, Inc. reported first-quarter 2026 revenue of $19.7 million, up 12.5% from $17.5 million a year earlier, driven by growth in both glaucoma and dry eye products. Net loss narrowed to $13.0 million from $14.2 million as higher gross profit offset increased legal costs.
Interventional Glaucoma revenue rose to $18.3 million, while Interventional Dry Eye revenue increased to $1.4 million after new reimbursement support. Gross margin held at 86.2%. The company ended the quarter with $85.0 million in cash and cash equivalents and $40.0 million of term loan principal outstanding.
A Delaware federal court’s final judgment in the Alcon litigation awarded $55.4 million in damages and a 10% ongoing royalty on Hydrus revenue, and triggered a $5.4 million litigation success fee, while related patent reexaminations at the USPTO continue.